Skip to main content
. 2017 Apr 4;28(6):1388–1398. doi: 10.1093/annonc/mdx076

Figure 3.

Figure 3.

KEYNOTE-001 treatment cohorts. Ipi, ipilimumab; PD-L1, programmed dealth ligand 1; Q2W, every 2 weeks; Q3W, every 3 weeks. Figure adapted with permission from Khoja et al. [40].